PE Tech Report

NEWSLETTER

Like this article?

Sign up to our free newsletter

Cure Ventures closes inaugural fund at $350m hard-cap

Cure Ventures, a life sciences venture capital firm focusing on company formation around curative technologies, has closed its inaugural fund, Cure Ventures Fund I, at its targeted hard-cap of $350 million in capital commitments. 

Cure Ventures (Cure), a life sciences venture capital firm focusing on company formation around curative technologies, has closed its inaugural fund, Cure Ventures Fund I, at its targeted hard-cap of $350 million in capital commitments. 

The fund is supported by a strong syndicate of both US and internationally-based investors that include state and city public pension funds, foundations and endowments, fund-of-funds, hospital and health systems, sovereign wealth funds and family offices.

Cure Ventures is focused on early-stage investments in life science and biotechnology, primarily focused in new therapeutics. Embedded Cure operators will work alongside portfolio company founders to drive day-to-day decision making.

Cure leverages a seed funding model, allowing for important de-risking activities – a critical step in the early drug development process. As part of this process, Cure intends to follow through and co-lead subsequent Series A and B rounds of promising companies.

Cure Ventures was founded by a network of highly accomplished industry veterans, including Managing Partners, Richard (Rich) Lim, MBA; David (Dave) Fallace, JD, MBA; and Lou Tartaglia, PhD. The managing partners have played major roles in the success of several biotechnology companies, including Juno Therapeutics, Agios Therapeutics, Nuvation Bio and many others.

 

Like this article? Sign up to our free newsletter

MOST POPULAR

FURTHER READING

Featured